Thymoquinone inhibits Escherichia coli ATP synthase and cell growth

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ahmad, Zulfiqar ^a   Laughlin, Thomas F ^a,b   Kady, Ismail O ^b  

^a A T STILL UNIVERSITY   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; THYMOQUINONE; BENZOQUINONE DERIVATIVE; CULTURE MEDIUM; ENZYME INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; CELL GROWTH; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ESCHERICHIA COLI; GROWTH INHIBITION; MEMBRANE BINDING; NONHUMAN; PROTEIN EXPRESSION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; PHYSIOLOGY;

ESCHERICHIA COLI;

ATP SYNTHETASE COMPLEXES; BENZOQUINONES; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; ESCHERICHIA COLI;

EID: 84930678197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127802     Document Type: Article

References (57)

1. Senior AE, Nadanaciva S, Weber J. The molecular mechanism of ATP synthesis by F1F0-ATP synthase. Biochim Biophys Acta. 2002; 1553(3):188-211. Epub 2002/05/09. S0005272802001858 [pii]. PMID: 11997128.
2. Abrahams JP, Leslie AGW, Lutter R, Walker JE. Structure at 2.8 A resolution of F1-ATPase from bovine heart mitochondria. Nature. 1994; 370(6491):621-8. PMID: 8065448
3. Weber J, Senior AE. ATP synthesis driven by proton transport in F1F0-ATP synthase. FEBS Lett. 2003; 545(1):61-70. Epub 2003/06/06. S0014579303003946 [pii]. PMID: 12788493.
4. Noji H, Yoshida M. The rotary machine in the cell, ATP synthase. J Biol Chem. 2001; 276(3):1665-8. Epub 2000/11/18. doi: 10.1074/jbc.R000021200 R000021200 [pii]. PMID: 11080505.
5. Ahmad Z, Cox JL. ATP Synthase: The Right Size Base Model for Nanomotors in Nanomedicine. The Scientific World Journal. 2014; 2014:10. doi: 10.1155/2014/567398
6. Cingolani G, Duncan TM. Structure of the ATP synthase catalytic complex (F(1)) from Escherichia coli in an autoinhibited conformation. Nat Struct Mol Biol. 2011; 18(6):701-7. Epub 2011/05/24. doi: 10.1038/nsmb.2058 nsmb.2058 [pii]. PMID: 21602818; PubMed Central PMCID: PMC3109198.
7. Hong S, Pedersen PL. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev. 2008; 72(4):590-641. Epub 2008/12/05. doi: 10.1128/MMBR.00016-08 72/4/590 [pii]. PMID: 19052322; PubMed Central PMCID: PMC2593570.
8. Ahmad Z, Laughlin TF. Medicinal chemistry of ATP synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides. Curr Med Chem. 2010; 17(25):2822-36. Epub 2010/07/01. BSP/CMC/E-Pub/ 172 [pii]. PMID: 20586714.
9. Rao SP, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2008; 105(33):11945-50. Epub 2008/08/14. doi: 10.1073/pnas.0711697105 0711697105 [pii]. PMID: 18697942; PubMed Central PMCID: PMC2575262.
10. Burwick NR, Wahl ML, Fang J, Zhong Z, Moser TL, Li B, et al. An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chem. 2005; 280(3):1740-5. Epub 2004/11/06. M405947200 [pii] doi: 10.1074/jbc.M405947200 PMID: 15528193; PubMed Central PMCID: PMC1201548.
11. Chang HY, Huang HC, Huang TC, Yang PC, Wang YC, Juan HF. Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. Cancer Res. 2012; 72(18):4696-706. Epub 2012/07/24. 0008-5472.CAN-12-0567 [pii] doi: 10.1158/0008-5472.CAN-12-0567 PMID: 22822083.
12. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005; 307(5707):223-7. Epub 2004/12/14. 1106753 [pii] doi: 10.1126/science.1106753 PMID: 15591164.
13. Johnson KM, Chen X, Boitano A, Swenson L, Opipari AW, Jr., Glick GD. Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. Chem Biol. 2005; 12(4):485-96. Epub 2005/04/27. S1074-5521(05)00070-0 [pii] doi: 10.1016/j.chembiol.2005.02.012 PMID: 15850986.
14. Yavlovich A, Viard M, Zhou M, Veenstra TD, Wang JM, Gong W, et al. Ectopic ATP synthase facilitates transfer of HIV-1 from antigen-presenting cells to CD4(+) target cells. Blood. 2012; 120(6):1246-53. Epub 2012/07/04. doi: 10.1182/blood-2011-12-399063 blood-2011-12-399063 [pii]. PMID: 22753871; PubMed Central PMCID: PMC3418719.
15. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol. 2000; 130(5):1115-23. Epub 2000/07/06. doi: 10.1038/sj.bjp.0703397 PMID: 10882397; PubMed Central PMCID: PMC1572158.
16. Pedersen PL. The cancer cell's "power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr. 2007; 39(1):1-12. Epub 2007/04/04. doi: 10.1007/s10863-007-9070-5 PMID: 17404823.
17. Piotto S, Concilio S, Sessa L, Porta A, Calabrese EC, Zanfardino A, et al. Small azobenzene derivatives active against bacteria and fungi. Eur J Med Chem. 2013; 68:178-84. Epub 2013/08/27. doi: 10.1016/j.ejmech.2013.07.030 S0223-5234(13)00478-9 [pii]. PMID: 23974017.
18. Li B, Vik SB, Tu Y. Theaflavins inhibit the ATP synthase and the respiratory chain without increasing superoxide production. J Nutr Biochem. 2012; 23(8):953-60. Epub 2011/09/20. doi: 10.1016/j.jnutbio.2011.05.001 S0955-2863(11)00149-5 [pii]. PMID: 21924889.
19. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A. 2007; 104(34):13632-7. Epub 2007/08/19. 0706290104 [pii] doi: 10.1073/pnas.0706290104 PMID: 17698806; PubMed Central PMCID: PMC1948022.
20. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009; 486(2):95-102. Epub 2009/06/11. PMID: 19514131; PubMed Central PMCID: PMC2749321.
21. Cushnie TP, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents. 2011; 38(2):99-107. Epub 2011/04/26. doi: 10.1016/j.ijantimicag.2011.02.014 S0924-8579(11)00130-0 [pii]. PMID: 21514796.
22. Singh CK, Pitschmann A, Ahmad N. Resveratrol-zinc combination for prostate cancer management. Cell Cycle. 2014; 13(12):1867-74. Epub 2014/05/29. doi: 10.4161/cc.29334 29334 [pii]. PMID: 24866157; PubMed Central PMCID: PMC4111750.
23. Duarte S, Gregoire S, Singh AP, Vorsa N, Schaich K, Bowen WH, et al. Inhibitory effects of cranberry polyphenols on formation and acidogenicity of Streptococcus mutans biofilms. FEMS Microbiol Lett. 2006; 257(1):50-6. Epub 2006/03/24. FML147 [pii] doi: 10.1111/j.1574-6968.2006.00147.x PMID: 16553831.
24. Dadi PK, Ahmad M, Ahmad Z. Inhibition of ATPase activity of Escherichia coli ATP synthase by polyphenols. Int J Biol Macromol. 2009; 45(1):72-9. Epub 2009/04/21. doi: 10.1016/j.ijbiomac.2009.04.004 S0141-8130(09)00071-3 [pii]. PMID: 19375450.
25. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 2010; 29:87. Epub 2010/07/03. doi: 10.1186/1756-9966-29-87 1756-9966-29-87 [pii]. PMID: 20594324; PubMed Central PMCID: PMC2909169.
26. Koka PS, Mondal D, Schultz M, Abdel-Mageed AB, Agrawal KC. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med (Maywood). 2010; 235(6):751-60. Epub 2010/06/01. doi: 10.1258/ebm.2010.009369 235/6/751 [pii]. PMID: 20511679.
27. Attoub S, Sperandio O, Raza H, Arafat K, Al-Salam S, Al Sultan MA, et al. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam Clin Pharmacol. 2013; 27(5):557-69. Epub 2012/07/14. doi: 10.1111/j.1472-8206.2012.01056.x PMID: 22788741.
28. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012; 83(4):443-51. Epub 2011/10/19. doi: 10.1016/j.bcp.2011.09.029 S0006-2952(11)00735-0 [pii]. PMID: 22005518.
29. Fararh KM, Shimizu Y, Shiina T, Nikami H, Ghanem MM, Takewaki T. Thymoquinone reduces hepatic glucose production in diabetic hamsters. Res Vet Sci. 2005; 79(3):219-23. Epub 2005/08/02. S0034-5288(05)00007-X [pii] doi: 10.1016/j.rvsc.2005.01.001 PMID: 16054891.
30. Kouidhi B, Zmantar T, Jrah H, Souiden Y, Chaieb K, Mahdouani K, et al. Antibacterial and resistance-modifying activities of thymoquinone against oral pathogens. Ann Clin Microbiol Antimicrob. 2011; 10:29. Epub 2011/06/29. doi: 10.1186/1476-0711-10-29 1476-0711-10-29 [pii]. PMID: 21707998; PubMed Central PMCID: PMC3146813.
31. Chaieb K, Kouidhi B, Jrah H, Mahdouani K, Bakhrouf A. Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation. BMC Complement Altern Med. 2011; 11:29. Epub 2011/04/15. doi: 10.1186/1472-6882-11-29 1472-6882-11-29 [pii]. PMID: 21489272; PubMed Central PMCID: PMC3095572.
32. Al-Majed AA, Al-Omar FA, Nagi MN. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol. 2006; 543(1-3):40-7. Epub 2006/07/11. S0014-2999(06)00573-5 [pii] doi: 10.1016/j.ejphar.2006.05.046 PMID: 16828080.
33. Salmani JM, Asghar S, Lv H, Zhou J. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules. 2014; 19(5):5925-39. Epub 2014/05/13. doi: 10.3390/molecules19055925 molecules19055925 [pii]. PMID: 24815311.
34. Chinnam N, Dadi PK, Sabri SA, Ahmad M, Kabir MA, Ahmad Z. Dietary bioflavonoids inhibit Escherichia coli ATP synthase in a differential manner. Int J Biol Macromol. 2010; 46(5):478-86. Epub 2010/03/30. doi: 10.1016/j.ijbiomac.2010.03.009 S0141-8130(10)00090-5 [pii]. PMID: 20346967; PubMed Central PMCID: PMC2862773.
35. Ketchum CJ, Al-Shawi MK, Nakamoto RK. Intergenic suppression of the gammaM23K uncoupling mutation in F0F1 ATP synthase by betaGlu-381 substitutions: the role of the beta380DELSEED386 segment in energy coupling. Biochem J. 1998; 330(2):707-12. PMID: 9480879
36. Senior AE, Latchney LR, Ferguson AM, Wise JG. Purification of F1-ATPase with impaired catalytic activity from partial revertants of Escherichia coli uncA mutant strains. Arch Biochem Biophys. 1984; 228(1):49-53. Epub 1984/01/01. 0003-9861(84)90045-6 [pii]. PMID: 6230049.
37. Senior AE, Langman L, Cox GB, Gibson F. Oxidative phosphorylation in Escherichia coli. Characterization of mutant strains in which F1-ATPase contains abnormal beta-subunits. Biochem J. 1983; 210(2):395-403. PMID: 6222731
38. Senior AE, Langman L, Cox GB, Gibson F. Oxidative phosphorylation in Escherichia coli. Characterization of mutant strains in which F1-ATPase contains abnormal beta-subunits. Biochem J. 1983; 210(2):395-403. Epub 1983/02/15. PMID: 6222731; PubMed Central PMCID: PMC1154237.
39. Weber J, Lee RS, Grell E, Wise JG, Senior AE. On the location and function of tyrosine beta 331 in the catalytic site of Escherichia coli F1-ATPase. J Biol Chem. 1992; 267(3):1712-8. Epub 1992/01/25. PMID: 1530942.
40. Taussky HH, Shorr E. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 1953; 202(2):675-85. Epub 1953/06/01. PMID: 13061491.
41. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. Epub 1970/08/15. PMID: 5432063.
42. Rao R, Perlin DS, Senior AE. The defective proton-ATPase of uncA mutants of Escherichia coli: ATP-binding and ATP-induced conformational change in mutant alpha-subunits. Arch Biochem Biophys. 1987; 255(2):309-15. Epub 1987/06/01. PMID: 2884928.
43. Ahmad Z, Senior AE. Modulation of charge in the phosphate binding site of Escherichia coli ATP synthase. J Biol Chem. 2005; 280(30):27981-9. Epub 2005/06/09. M503955200 [pii] doi: 10.1074/jbc.M503955200 PMID: 15939739.
44. Singh CK, George J, Ahmad N. Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci. 2013; 1290:113-21. Epub 2013/07/17. doi: 10.1111/nyas.12160 PMID: 23855473; PubMed Central PMCID: PMC3713511.
45. Ahmad A, Khan A, Yousuf S, Khan LA, Manzoor N. Proton translocating ATPase mediated fungicidal activity of eugenol and thymol. Fitoterapia. 2010; 81(8):1157-62. Epub 2010/07/28. doi: 10.1016/j.fitote.2010.07.020 S0367-326X(10)00197-8 [pii]. PMID: 20659536.
46. Ahmad I, Muneer KM, Tamimi IA, Chang ME, Ata MO, Yusuf N. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol Appl Pharmacol. 2013; 270(1):70-6. Epub 2013/04/16. doi: 10.1016/j.taap.2013.03.027 S0041-008X(13)00136-1 [pii]. PMID: 23583630.
47. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol. 2004; 25(4):857-66. Epub 2004/09/18. PMID: 15375533.
48. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, et al. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 2010; 62(7):938-46. Epub 2010/10/07. doi: 10.1080/01635581.2010.509832 927591507 [pii]. PMID: 20924969; PubMed Central PMCID: PMC4167365.
49. Ahmad Z, Senior AE. Mutagenesis of residue betaArg-246 in the phosphate-binding subdomain of catalytic sites of Escherichia coli F1-ATPase. J Biol Chem. 2004; 279(30):31505-13. Epub 2004/05/20. doi: 10.1074/jbc.M404621200 M404621200 [pii]. PMID: 15150266.
50. Laughlin TF, Ahmad Z. Inhibition of Escherichia coli ATP synthase by amphibian antimicrobial peptides. Int J Biol Macromol. 2010; 46(3):367-74. Epub 2010/01/27. doi: 10.1016/j.ijbiomac.2010.01.015 S0141-8130(10)00025-5 [pii]. PMID: 20100509; PubMed Central PMCID: PMC2834880.
51. Li W, Brudecki LE, Senior AE, Ahmad Z. Role of {alpha}-subunit VISIT-DG sequence residues Ser-347 and Gly-351 in the catalytic sites of Escherichia coli ATP synthase. J Biol Chem. 2009; 284(16):10747-54. Epub 2009/02/26. doi: 10.1074/jbc.M809209200 M809209200 [pii]. PMID: 19240022; PubMed Central PMCID: PMC2667762.
52. Ahmad Z, Winjobi M, Kabir MA. Significance of alphaThr-349 in the Catalytic Sites of Escherichia coli ATP Synthase. Biochemistry. 2014; 53(47):7376-85. Epub 2014/11/07. doi: 10.1021/bi5013063 PMID: 25375895; PubMed Central PMCID: PMC4255642.
53. Ahmad Z, Tayou J, Laughlin TF. Asp residues of betaDELSEED-motif are required for peptide binding in the Escherichia coli ATP synthase. Int J Biol Macromol. 2015; 75C:37-43. Epub 2015/01/21. S0141-8130(15)00024-0 [pii] doi: 10.1016/j.ijbiomac.2014.12.047 PMID: 25603139.
54. Ahmad Z, Ahmad M, Okafor F, Jones J, Abunameh A, Cheniya RP, et al. Effect of structural modulation of polyphenolic compounds on the inhibition of Escherichia coli ATP synthase. Int J Biol Macromol. 2012; 50(3):476-86. Epub 2012/01/31. doi: 10.1016/j.ijbiomac.2012.01.019 S0141-8130(12)00021-9 [pii]. PMID: 22285988.
55. Ragheb A, Attia A, Eldin WS, Elbarbry F, Gazarin S, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl. 2009; 20(5):741-52. Epub 2009/09/09. SaudiJKidneyDisTranspl-2009-20-5-741-55356 [pii]. PMID: 19736468.
56. Kokoska L, Havlik J, Valterova I, Sovova H, Sajfrtova M, Jankovska I. Comparison of chemical composition and antibacterial activity of Nigella sativa seed essential oils obtained by different extraction methods. J Food Prot. 2008; 71(12):2475-80. Epub 2009/02/28. PMID: 19244901.
57. Chandra S, Mondal D, Agrawal KC. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. Exp Biol Med (Maywood). 2009; 234(4):442-53. Epub 2009/02/24. doi: 10.3181/0811-RM-317 0811-RM-317 [pii]. PMID: 19234050.